WELL Health Q4 2025 slides: record profits, strategic US exit underway

WELL Health reported FY2025 revenue of $1.40B (+52% YoY) and adjusted EBITDA of $203.7M (+336%), with adjusted EPS CAD 0.20 beating forecasts by ~93% (vs CAD 0.1035). Management announced strategic alternatives for U.S. care assets (Circle Medical, CRH, wisp) and guidance for 2026 revenue $1.55–1.65B and adjusted EBITDA $175–185M, while normalized metrics (ex-U.S. assets) show more moderate growth. Shares traded down ~2–3% after the release, reflecting concerns over valuation and growth sustainability post-divestiture despite strong cash flow ($58.2M FCF) and accelerating Canadian clinic and tech platform momentum.

Analysis

Management’s decision to remove U.S. care businesses from the consolidated story materially changes the leverage and multiple dynamics investors should model: the company becomes a higher-margin, more concentration-risk play where near-term valuation will be driven by the ability to recycle sale proceeds into Canadian clinic consolidation and the tech spin‑out rather than by headline revenue growth. Expect the market to apply a bifurcated valuation — a private-market multiple for disposed U.S. assets and a public SaaS/healthcare services multiple for the residual business — which creates windows where intrinsic value and market price can diverge for months.

Second-order beneficiaries include vendors and partners that plug into the clinic network: EMR/appointment vendors, diagnostics suppliers, and regional staffing agencies that can scale with a concentrated operator. Conversely, U.S. telehealth consolidators and pure-play national roll-up acquirers face a buyer’s market for non-core assets, which will compress exit multiples and could depress M&A comps for the sector for 6–12 months. The technology spin‑out is the highest optionality item — if structured with clean KPI disclosure (MRR, retention, gross margins), it can re‑trade at a materially higher multiple than the blended parent.

Primary execution risks are valuation risk on U.S. disposals (pressured by sector comps), integration risk on rapid Canadian clinic roll-ups, and execution/timing risk on the spin‑out’s governance and tax structure. Key near-term catalysts are definitive sale announcements, documentation for the spin‑out, and conversion of the M&A pipeline into closed acquisitions — each event can create 20–40% re-rating moves depending on deal terms and buyer identity.

Key Decisions for Investors

• Event-driven long WELL.TO (ticker: WELL.TO): Initiate on either a >15% intraday pullback or within 2 trading days after a definitive U.S. asset sale announcement. Time horizon 6–12 months; target +40–60% if proceeds are redeployed into high‑margin Canadian rollups or the spin‑out receives clear valuation metrics; hard stop -30% if sales close below consensus private-market comps or guidance is cut.
• Hedged equity collar for capital preservation (ticker: WELL.TO): Buy equity and simultaneously buy a 12‑month put ~25% OTM while selling a 3‑6 month call ~10% OTM to finance the put. Time horizon 12 months; objective is to capture upside from spin‑out rerating while limiting downside to ~25% paid via put premium — suitable for size-limited exposure with defined tail-risk protection.
• Relative-value pair: long WELL.TO / short TDOC (tickers: WELL.TO long, TDOC short): Size the short to hedge ~50–60% of beta; time horizon 3–9 months. Rationale: isolate company-specific execution on Canadian consolidation and spin‑out optionality while shorting the macro-sensitive U.S. telehealth narrative; target asymmetric payoff where a successful spin‑out drives WELL re‑rating while secular telehealth multiple compression continues.
• Event-focused options speculative: Buy 6–12 month calls on WELL.TO after spin‑out S-1/MD&A or after an announced bid for U.S. assets (if implied vol drops post-announcement). Time horizon 6–12 months; risk entire premium, reward multibagger if the market prices the tech spin‑out at a true SaaS multiple — use this only as a small, high-conviction sleeve tied to specific filings.